Margaret Shipp

Margaret Shipp, MD, is the Chief, Division of Hematologic Neoplasia at the Dana-Farber Cancer Institute (DFCI) and the Professor of Medicine at Harvard Medical School. Her research focuses on investigating the clinical and molecular heterogeneity of aggressive B‑cell lymphomas, including diffuse large B‑cell lymphoma (DLBCL), related LBCL subtypes and classical Hodgkin lymphoma (cHL). Dr. Shipp has led efforts to define molecular signatures of DLBCLs and Hodgkin lymphomas, identify biologically distinct subsets of these diseases, and characterize associated rational treatment targets including modulators of the host anti-tumor immune response. The Shipp group identified a genetic basis for PD1-mediated immune evasion and sensitivity to PD1 blockade in cHL. Building upon these studies, her group has analyzed the defining features of the intact tumor microenvironment and circulating immune signature in patients with cHL. The Shipp lab is also developing parsimonious genetic signatures for clinical use in disease diagnosis and therapy and creating murine models of discrete lymphoma subtypes to examine the stages of tumor progression and immune escape mechanisms.